Phase II Trial of Trilaciclib added to Chemotherapy plus Pembrolizumab in the First-line Treatment of patients with Advanced Non-Small Cell Lung Cancer.
Associated Conditions
Lung CancerPrincipal Investigator
George Simon
Sponsor
G1 Therapeutics 1658472